# Patent

## Title
4-amino-2-(2-pyridyl)pyrimidines as microbicidal active substances

## Abstract

Compounds of formula 



wherein

    R1 and R2 are each independently of the other hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C20alkyl, C1–C20alkoxy, C2–C20alkenyl, C2–C20alkynyl, C3–C18cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; mono- or di-C1–C20alkylamino; C1–C6alkylamino-C1–C20alkyl; halogen; phenyl; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl-C1–C20alkyl, phenoxy or phenyl-C1–C20alkoxy; or R1 and R2 form a polymethylene chain of formula —(CH2)m— wherein m=2–12;
    R3 is unsubstituted C7–C20alkyl; or amino-, hydroxy-, carboxy- or C1–C6alkyloxycarbonyl-substituted C2–C20alkyl; C8–C18cycloalkyl; C8–C20alkenyl; C8–C20alkynyl; C3–C7cycloalkyl-C8–C20alkyl; C1–C4alkoxy-C8–C20alkyl; R7R8N—C7–C20alkyl; phenyl; phenyl-C1–C4alkyl; or phenyl-C1–C4alkoxy;
    R4 is hydrogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted C1–C20alkyl, C2–C20alkenyl, C2–C20alkynyl, C3–C20cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl, C1–C20alkoxy-C1–C6alkyl or R7R8N—C1–C20alkyl, phenyl, phenyl-C1–C20alkyl or phenoxy-C1–C20alkyl;
    R5 and R6 are each independently of the other hydrogen; C1–C20alkyl; C2–C20alkenyl; C2–C20-alkynyl; C3–C18cycloalkyl; C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C2–C20alkoxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; nitro; C1–C20alkylamino; C1–C20alkylaminoalkyl; C1–C20haloalkyl; C1–C20haloalkoxy; halogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl, phenoxy or phenyl-C1–C20alkyl or phenyl-C1–C20alkoxy; or R5 and R6 together form a polymethylene chain of formula —(CH2)m— wherein m=2–12; and
    R7 and R8 are each independently of the other hydrogen; C1–C20alkyl; C3–C20alkenyl; C3–C20alkynyl; C3–C7cycloalkyl; C3–C20cycloalkyl-C1–C4alkyl; phenyl; or phenyl-C1–C4alkyl are suitable for the antimicrobial treatment of surfaces.

## Background
The present invention relates to substituted 4-amino-2-(2-pyridyl)pyrimidines, to the preparation of such compounds, and to their use for the antimicrobial treatment of surfaces, as antimicrobial active substances against gram-positive and gram-negative bacteria, yeasts and fungi and also in the preservation of cosmetics, household products, textiles and plastics and for use in disinfectants.
The substituted 4-amino-2-(2-pyridyl)pyrimidines according to the invention correspond to formula 



wherein

    R1 and R2 are each independently of the other hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C20alkyl, C1–C20alkoxy, C2–C20alkenyl, C2–C20alkynyl, C3–C18cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyl-oxycarbonyl; cyano; mono- or di-C1–C20alkylamino; C1–C6alkylamino-C1–C20alkyl; halogen; phenyl; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl-C1–C20alkyl, phenoxy or phenyl-C1–C20alkoxy; or R1 and R2 form a polymethylene chain of formula —(CH2)m— wherein m=2–12;
    R3 is unsubstituted C7–C20alkyl; or amino-, hydroxy-, carboxy- or C1–C6alkyloxycarbonyl-substituted C2–C20alkyl, C8–C18cycloalkyl, C8–C20alkenyl, C8–C20alkynyl, C3–C7cycloalkyl-C8–C20alkyl, C1–C4alkoxy-C8–C20alkyl, R7R8N—C7–C20alkyl, phenyl, phenyl-C1–C4alkyl or phenyl-C1–C4alkoxy;
    R4 is hydrogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted C1–C20alkyl, C2–C20alkenyl, C2–C20alkynyl, C3–C20cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl, C1–C20alkoxy-C1–C6alkyl or R7R8N—C1–C20alkyl, phenyl, phenyl-C1–C20alkyl or phenoxy-C1–C20alkyl;
    R5 and R6 are each independently of the other hydrogen; C1–C20alkyl; C2–C20alkenyl; C2–C20-alkynyl; C3–C18cycloalkyl; C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C2–C20alkoxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; nitro; C1–C20alkylamino; C1–C20alkylaminoalkyl; C1–C20haloalkyl; C1–C20haloalkoxy; halogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl, phenoxy or phenyl-C1–C20alkyl or phenyl-C1–C20alkoxy; or R5 and R6 together form a polymethylene chain of formula —(CH2)m— wherein m=2–12; and
    R7 and R8 are each independently of the other hydrogen; C1–C20alkyl; C3–C20alkenyl; C3–C20-alkynyl; C3–C7cycloalkyl; C3–C20cycloalkyl-C1–C4alkyl; phenyl; or phenyl-C1–C4alkyl.


C1–C20Alkyl radicals are straight-chain or branched alkyl radicals, for example methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, amyl, isoamyl or tert-amyl, heptyl, octyl, isooctyl, nonyl, decyl, undecyl, dodecyl, tetradecyl, pentadecyl, hexadecyl, heptadecyl, octadecyl or eicosyl.
C3–C18Cycloalkyl denotes, for example, cyclopropyl, cyclobutyl, cyclopentyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, cyclotetradecyl, cyclopentadecyl, cyclohexadecyl, cycloheptadecyl, cyclooctadecyl or, especially, cyclohexyl.
Alkenyl includes, within the scope of the meanings given, inter alia, allyl, isopropenyl, 2-butenyl, 3-butenyl, isobutenyl, n-penta-2,4-dienyl, 3-methyl-but-2-enyl, n-oct-2-enyl, n-dodec-2-enyl, isododecenyl, n-dodec-2-enyl and n-octadec-4-enyl.
C1–C5Alkoxy radicals are straight-chain or branched radicals, for example methoxy, ethoxy, propoxy, butoxy or pentyloxy.
Alkynyl includes, for example, ethynyl, propargyl, 2-butynyl, 1-pentynyl and 2-pentynyl.
Preference is given to compounds of formula (1) wherein

    R5 and R6 are each independently of the other hydrogen or C1–C20alkyl, very especially hydrogen.
    R1 and R2 in formula (1) are, each independently of the other, preferably hydrogen, unsubstituted or mono- or poly-halo-substituted C1–C20alkyl; or C1–C5alkoxy-C1–C5alkyl; especially hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C5alkyl; or C1–C3alkoxy-C1–C5alkyl; and more especially hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3 wherein m is from 1 to 4.
    R3 in formula (1) is preferably unsubstituted or amino-substituted C7–C20alkyl, C3–C7cycloalkyl-C8–C20alkyl, C1–C4alkoxy-C7–C20alkyl, R7R8N—C7–C20alkyl, phenyl-C1–C4alkyl or phenyl-C1–C6alkoxy, especially unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl.


Especially preferred compounds of formula (1) are those wherein

    R1 and R2 are each independently of the other hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3;
    R3 is unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl;
    R4 is hydrogen or C1–C20alkyl;
    R5, R6, R7 and R8 are each independently of the others hydrogen or C1–C20alkyl; and
    m is from 1 to 4,

especially those wherein

    R5, R6, R7 and R8 are hydrogen.


Special preference is given to compounds of formulae 



    n is from 7 to 20; and
    R1, R2, R3, R5 and R6 are as defined for formula (1).


All those compounds may also be present in the form of their acid addition salts, suitable acids being: HF, HCl, HBr, H2SO4, H3PO4, mono- and di-functional carboxylic acids, for example lactic acid, tartaric acid, acetic acid, maleic acid, fumaric acid, citric acid and salicylic acid, or sulfonic acid.
Table 1 below lists further 4-amino-2-(2-pyridyl)pyrimidines according to the invention by way of example:







TABLE 1







General formula








 










Compound





of


formula
R1
R2
R3





 4
—CH3
—C2H5
—NH—(CH2)7—NH2


 5
—CH3
—C2H5
—NH—(CH2)8—NH2


 6
—CH3
—C2H5
—NH—(CH2)9—NH2


 7
—CH3
—C2H5
—NH—(CH2)12—NH2


 8
—CH3
—C2H5
—NH—(CH2)6—CH3


 9
—CH3
—C2H5
—NH—(CH2)7—CH3


10
—CH3
—C2H5
—NH—(CH2)8—CH3


11
—CH3
—C2H5
—NH—(CH2)9—CH3


12
—CH3
—C2H5
—NH—(CH2)11—CH3


13
—CH3
—C2H5
—NH—(CH2)15—CH3


 


14
—CH3
—C2H5






 


15
—CH3
—C2H5






 


16
—CH3
—H
—NH—(CH2)7—NH2


17
—CH3
—H
—NH—(CH2)8—NH2


18
—CH3
—H
—NH—(CH2)9—NH2


19
—CH3
—H
—NH—(CH2)12—NH2


20
—CH3
—H
—NH—(CH2)6—CH3


21
—CH3
—H
—NH—(CH2)7—CH3


22
—CH3
—H
—NH—(CH2)8—CH3


23
—CH3
—H
—NH—(CH2)9—CH3


24
—CH3
—H
—NH—(CH2)11—CH3


25
—CH3
—H
—NH—(CH2)15—CH3


 


26
—CH3
—H






 


27
—CH3
—H






 


28
—CF3
—H
—NH—(CH2)7—NH2


29
—CF3
—H
—NH—(CH2)8—NH2


30
—CF3
—H
—NH—(CH2)9—NH2


31
—CF3
—H
—NH—(CH2)12—NH2


32
—CF3
—H
—NH—(CH2)6—CH3


33
—CF3
—H
—NH—(CH2)7—CH3


34
—CF3
—H
—NH—(CH2)8—CH3


35
—CF3
—H
—NH—(CH2)9—CH3


36
—CF3
—H
—NH—(CH2)11—CH3


37
—CF3
—H
—NH—(CH2)15—CH3


 


38
—CF3
—H






 


39
—CF3
—H






 


40
-isopropyl
—H
—NH—(CH2)7—NH2


41
-isopropyl
—H
—NH—(CH2)8—NH2


42
-isopropyl
—H
—NH—(CH2)9—NH2


43
-isopropyl
—H
—NH—(CH2)12—NH2


44
-isopropyl
—H
—NH—(CH2)6—CH3


45
-isopropyl
—H
—NH—(CH2)7—CH3


46
-isopropyl
—H
—NH—(CH2)8—CH3


47
-isopropyl
—H
—NH—(CH2)9—CH3


48
-isopropyl
—H
—NH—(CH2)11—CH3


49
-isopropyl
—H
—NH—(CH2)15—CH3


 


50
-isopropyl
—H






 


51
-isopropyl
—H






 


52
-tert-butyl
—H
—NH—(CH2)7—NH2


53
-tert-butyl
—H
—NH—(CH2)8—NH2


54
-tert-butyl
—H
—NH—(CH2)9—NH2


55
-tert-butyl
—H
—NH—(CH2)12—NH2


56
-tert-butyl
—H
—NH—(CH2)6—CH3


57
-tert-bulyl
—H
—NH—(CH2)7—CH3


58
-tert-butyl
—H
—NH—(CH2)8—CH3


59
-tert-butyl
—H
—NH—(CH2)9—CH3


60
-tert-butyl
—H
—NH—(CH2)11—CH3


61
-tert-butyl
—H
—NH—(CH2)15—CH3


 


62
-tert-butyl
—H






 


63
-tert-butyl
—H






 


64
—CH3
-isopropyl
—NH—(CH2)7—NH2


65
—CH3
-isopropyl
—NH—(CH2)8—NH2


66
—CH3
-isopropyl
—NH—(CH2)9—NH2


67
—CH3
-isopropyl
—NH—(CH2)12—NH2


68
—CH3
-isopropyl
—NH—(CH2)6—CH3


69
—CH3
-isopropyl
—NH—(CH2)7—CH3


70
—CH3
-isopropyl
—NH—(CH2)8—CH3


71
—CH3
-isopropyl
—NH—(CH2)9—CH3


72
—CH3
-isopropyl
—NH—(CH2)11—CH3


73
—CH3
-isopropyl
—NH—(CH2)15—CH3


 


74
—CH3
-isopropyl






 


75
—CH3
-isopropyl






 


76
—(CH2)2—O—CH3
—H
—NH—(CH2)7—NH2


77
—(CH2)2—O—CH3
—H
—NH—(CH2)8—NH2


78
—(CH2)2—O—CH3
—H
—NH—(CH2)9—NH2


79
—(CH2)2—O—CH3
—H
—NH—(CH2)12—NH2


80
—(CH2)2—O—CH3
—H
—NH—(CH2)6—CH3


81
—(CH2)2—O—CH3
—H
—NH—(CH2)7—CH3


82
—(CH2)2—O—CH3
—H
—NH—(CH2)8—CH3


83
—(CH2)2—O—CH3
—H
—NH—(CH2)9—CH3


84
—(CH2)2—O—CH3
—H
—NH—(CH2)11—CH3


85
—(CH2)2—O—CH3
—H
—NH—(CH2)15—CH3


 


86
—(CH2)2—O—CH3
—H






 


87
—(CH2)2—O—CH3
—H






 


88
—CH3
—C2H5






 


89
—CH3
—C2H5
—NH—(CH2)10—CH3


90
—CH3
—C2H5
—NH—(CH2)14—CH3


 


91
—CH3
—H






 


92
—CH3
—H
—NH—(CH2)10—CH3


93
—CH3
—H
—NH—(CH2)14—CH3


 


94
—CF3
—H






 


95
—CF3
—H
—NH—(CH2)10—CH3


96
—CF3
—H
—NH—(CH2)14—CH3


 


97
-isopropyl
—H






 


98
-isopropyl
—H
—NH—(CH2)10—CH3


99
-isopropyl
—H
—NH—(CH2)14—CH3









The novel 4-amino-2-(2-pyridyl)pyrimidines are prepared by methods known per se (J. Org. Chem.; 1967, 32, 1591). For that purpose, 2-cyanopyridine is reacted, in a suitable solvent, for example methanol, ethanol, isopropanol, DMF, tetrahydrofuran etc., with ammonium acetate or ammonium chloride at a temperature of from −10° C. to 100° C. over a period of from 1 hour to 24 hours to form the corresponding 2-amidinopyridine. The 2-amidinopyridine is then condensed with an appropriate β-keto ester using an auxiliary base, for example sodium carbonate, potassium hydroxide, sodium ethanolate, sodium methanolate, potassium tert-butanolate etc., in a suitable solvent, for example methanol, ethanol, butanol, tert-butanol, THF, DMF, acetonitrile, toluene, xylene etc., over a period of from 1 to 24 hours at a temperature of from 40 to 120° C. The 4-hydroxy-2-(2-pyridyl)pyrimidine thereby obtained is then converted into the corresponding 4-chloro-2-(2-pyridyl)pyrimidine by conventional methods using phosphorus oxychloride. The substituted 4-amino-2-(2-pyridyl)pyrimidines are obtained by reacting the 4-chloro-2-(2-pyridyl)pyrimidine with primary or secondary amines in a suitable solvent, for example DMF, dioxane, toluene, xylene, ethanol, butanol, and an auxiliary base, for example triethylamine, DIEA, sodium carbonate, potassium hydroxide etc., or using an excess of amine at from 40 to 130° C. over a period of from 1 to 24 hours. Preparation of the compounds of formula (2), except for the reaction with polymer-bound diamines, is analogous to that of compound (1). The polymer-bound diamines are obtained by reacting an excess of from 2 to 10 equivalents of diamine in, for example, DMF, dichloromethane, THF or dioxane with trityl chloride polystyrene resin at a temperature of from 10 to 50° C. over a period of from 0.5 to 24 hours. From 2 to 10 equivalents of appropriately substituted 4-chloro-2-(2-pyridyl)pyrimidines are then reacted, in a suitable solvent, for example dichloromethane, DMF, THF or toluene, with the polymer-bound diamines at from 10 to 120° C. over a period of from 2 to 48 hours. After washing the resin to remove the excess, the target compounds are split off using from 1 to 30% trifluoroacetic acid in dichloromethane at 25° C. over a period of from 1 to 5 hours. For the purpose of further purification, the substances are freeze-dried from tBuOH/water 4:1 with from 1 to 10% HOAc and once from tBuOH/water 4:1.
The entire reaction proceeds according to the following scheme, where the roman numerals in the reaction scheme refer to the reaction steps: 



The compounds of formula (3) are prepared analogously to preparation of the compounds of formula (1) according to the following scheme, where the roman numerals in the reaction scheme refer to the reaction steps: 



The 4-amino-2-(2-pyridyl)pyrimidines used in accordance with the invention exhibit pronounced antimicrobial action, especially against pathogenic gram-positive and gram-negative bacteria and against bacteria of the skin flora, and also against yeasts and moulds. They are accordingly suitable especially for disinfection, deodorisation, and for general and antimicrobial treatment of the skin and mucosa and of integumentary appendages (hair), more especially for the disinfection of hands and wounds.
They are accordingly suitable as antimicrobial active substances and preservatives in personal care preparations, for example shampoos, bath additives, haircare preparations, liquid and solid soaps (based on synthetic surfactants and salts of saturated and/or unsaturated fatty acids), lotions and creams, deodorants, other aqueous or alcoholic solutions, e.g. cleansing solutions for the skin, moist cleaning cloths, oils or powders.
The invention accordingly relates also to a personal care preparation comprising at least one compound of formula (1) and cosmetically tolerable carriers or adjuvants.
The personal care preparation according to the invention contains from 0.01 to 15% by weight, preferably from 0.1 to 10% by weight, based on the total weight of the composition, of a compound of formula (1), and cosmetically tolerable adjuvants.
Depending upon the form of the personal care preparation, it comprises, in addition to the 4-amino-2-(2-pyridyl)pyrimidine of formula (1), further constituents, for example sequestering agents, colourings, perfume oils, thickening or solidifying agents (consistency regulators), emollients, UV-absorbers, skin protective agents, antioxidants, additives that improve the mechanical properties, such as dicarboxylic acids and/or aluminium, zinc, calcium or magnesium salts of C14–C22fatty acids, and, optionally, preservatives.
The personal care preparation according to the invention may be in the form of a water-in-oil or oil-in-water emulsion, an alcoholic or alcohol-containing formulation, a vesicular dispersion of an ionic or non-ionic amphiphilic lipid, a gel, a solid stick or an aerosol formulation.
As a water-in-oil or oil-in-water emulsion, the cosmetically tolerable adjuvant contains preferably from 5 to 50% of an oil phase, from 5 to 20% of an emulsifier and from 30 to 90% water. The oil phase may comprise any oil suitable for cosmetic formulations, for example one or more hydrocarbon oils, a wax, a natural oil, a silicone oil, a fatty acid ester or a fatty alcohol. Preferred mono- or poly-ols are ethanol, isopropanol, propylene glycol, hexylene glycol, glycerol and sorbitol.
Cosmetic formulations according to the invention are used in various fields. There come into consideration, for example, especially the following preparations:

    
    
        skin-care preparations, e.g. skin-washing and cleansing preparations in the form of tablet-form or liquid soaps, synthetic detergents or washing pastes,
        bath preparations, e.g. liquid (foam baths, milks, shower preparations) or solid bath preparations, e.g. bath cubes and bath salts;
        skin-care preparations, e.g. skin emulsions, multi-emulsions or skin oils;
        cosmetic personal care preparations, e.g. facial make-up in the form of day creams or powder creams, face powder (loose or pressed), rouge or cream make-up, eye-care preparations, e.g. eyeshadow preparations, mascaras, eyeliners, eye creams or eye-fix creams; lip-care preparations, e.g. lipsticks, lip gloss, lip contour pencils, nail-care preparations, such as nail varnish, nail varnish removers, nail hardeners or cuticle removers;
        intimate hygiene preparations, e.g. intimate washing lotions or intimate sprays;
        foot-care preparations, e.g. foot baths, foot powders, foot creams or foot balsams, special deodorants and antiperspirants or callus-removing preparations;
        light-protective preparations, such as sun milks, lotions, creams or oils, sun-blocks or tropicals, pre-tanning preparations or after-sun preparations;
        skin-tanning preparations, e.g. self-tanning creams;
        depigmenting preparations, e.g. preparations for bleaching the skin or skin-lightening preparations;
        insect-repellents, e.g. insect-repellent oils, lotions, sprays or sticks;
        deodorants, such as deodorant sprays, pump-action sprays, deodorant gels, sticks or roll-ons;
        antiperspirants, e.g. antiperspirant sticks, creams or roll-ons;
        preparations for cleansing and caring for blemished skin, e.g. synthetic detergents (solid or liquid), peeling or scrub preparations or peeling masks;
        hair-removal preparations in chemical form (depilation), e.g. hair-removing powders, liquid hair-removing preparations, cream or paste-form hair-removing preparations, hair-removing preparations in gel form or aerosol foams;
        shaving preparations, e.g. shaving soap, foaming shaving creams, non-foaming shaving creams, foams and gels, preshave preparations for dry shaving, aftershaves or aftershave lotions;
        fragrance preparations, e.g. fragrances (eau de Cologne, eau de toilette, eau de parfum, parfum de toilette, perfume), perfume oils or perfume creams;
        dental care, denture-care and mouth-care preparations, e.g. toothpastes, gel toothpastes, tooth powders, mouthwash concentrates, anti-plaque mouthwashes, denture cleaners or denture fixatives;
        cosmetic hair-treatment preparations, e.g. hair-washing preparations in the form of shampoos and conditioners, hair-care preparations, e.g. pretreatment preparations, hair tonics, styling creams, styling gels, pomades, hair rinses, treatment packs, intensive hair treatments, hair-structuring preparations, e.g. hair-waving preparations for permanent waves (hot wave, mild wave, cold wave), hair-straightening preparations, liquid hair-setting preparations, hair foams, hairsprays, bleaching preparations, e.g. hydrogen peroxide solutions, lightening shampoos, bleaching creams, bleaching powders, bleaching pastes or oils, temporary, semi-permanent or permanent hair colorants, preparations containing self-oxidising dyes, or natural hair colorants, such as henna or camomile.
    
    


An antimicrobial soap has, for example, the following composition:

    0.01 to 5% by weight of a compound of formula (1)
    0.3 to 1% by weight titanium dioxide,
    1 to 10% by weight stearic acid,
    soap base ad 100%, e.g. a sodium salt of tallow fatty acid or coconut fatty acid, or glycerol.


A shampoo has, for example, the following composition:

    0.01 to 5% by weight of a compound of formula (1),
    12.0% by weight sodium laureth-2-sulfate,
    4.0% by weight cocamidopropyl betaine,
    3.0% by weight NaCl and
    water ad 100%.


A deodorant has, for example, the following composition:

    0.01 to 5% by weight of a compound of formula (1),
    60% by weight ethanol,
    0.3% by weight perfume oil, and
    water ad 100%.


The invention relates also to an oral composition containing from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1), and orally tolerable adjuvants.
Example of an Oral Composition:

    10% by weight sorbitol,
    10% by weight glycerol,
    15% by weight ethanol,
    15% by weight propylene glycol,
    0.5% by weight sodium lauryl sulfate,
    0.25% by weight sodium methylcocyl taurate,
    0.25% by weight polyoxypropylene/polyoxyethylene block copolymer,
    0.10% by weight peppermint flavouring,
    0.1 to 0.5% by weight of a compound of formula (1), and
    48.6% by weight water.


The oral composition according to the invention may be, for example, in the form of a gel, a paste, a cream or an aqueous preparation (mouthwash).
The oral composition according to the invention may also comprise compounds that release fluoride ions which are effective against the formation of caries, for example inorganic fluoride salts, e.g. sodium, potassium, ammonium or calcium fluoride, or organic fluoride salts, e.g. amine fluorides, which are known under the trade name Olafluor.
The 4-amino-2-(2-pyridyl)pyrimidines of formula (1) used in accordance with the invention are also suitable for treating, especially preserving, textile fibre materials. Such materials are undyed and dyed or printed fibre materials, e.g. of silk, wool, polyamide or polyurethanes, and especially cellulosic fibre materials of all kinds. Such fibre materials are, for example, natural cellulose fibres, such as cotton, linen, jute and hemp, as well as cellulose and regenerated cellulose. Preferred suitable textile fibre materials are made of cotton.
The 4-amino-2-(2-pyridyl)pyrimidines according to the invention are suitable also for treating, especially imparting antimicrobial properties to or preserving, plastics, e.g. polyethylene, polypropylene, polyurethane, polyester, polyamide, polycarbonate, latex etc. Fields of use therefor are, for example, floor coverings, plastics coatings, plastics containers and packaging materials; kitchen and bathroom utensils (e.g. brushes, shower curtains, sponges, bathmats), latex, filter materials (air and water filters), plastics articles used in the field of medicine, e.g. dressing materials, syringes, catheters etc., so-called “medical devices”, gloves and mattresses.
Paper, for example papers used for hygiene purposes, may also be provided with antimicrobial properties using the 4-amino-2-(2-pyridyl)pyrimidines according to the invention.
It is also possible for nonwovens, e.g. nappies/diapers, sanitary towels, panty liners, and cloths for hygiene and household uses, to be provided with antimicrobial properties in accordance with the invention.
The 4-amino-2-(2-pyridyl)pyrimidines of formula (1) are also used in washing and cleaning formulations, e.g. in liquid or powder washing agents or softeners.
The 4-amino-2-(2-pyridyl)pyrimidines of formula (1) can also be used especially in household and general-purpose cleaners for cleaning and disinfecting hard surfaces.
A cleaning preparation has, for example the following composition:

    0.01 to 5% by weight of a compound of formula (1)
    3.0% by weight octyl alcohol 4EO
    1.3% by weight fatty alcohol C8–C10polyglucoside
    3.0% by weight isopropanol
    water ad 100%.


In addition to preserving cosmetic and household products, the preservation of technical products, the provision of technical products with antimicrobial properties and use as a biocide in technical processes are also possible, for example in paper treatment, especially in paper treatment liquors, printing thickeners of starch or cellulose derivatives, surface-coatings and paints.
The 4-amino-2-(2-pyridyl)pyrimidines of formula (1) are also suitable for the antimicrobial treatment of wood and for the antimicrobial treatment of leather, the preserving of leather and the provision of leather with antimicrobial properties.
The compounds according to the invention are also suitable for the protection of cosmetic products and household products from microbial damage.
The following Examples illustrate, but do not limit, the present invention.


PREPARATION EXAMPLES
Example 1
Synthesis of Substituted 4-amino-2-(2-pyridyl)pyrimidines
1a: Preparation of 2-(2-pyridyl)pyrimidines 



Sodium (1.44 g; 63 mmol) is dissolved, under nitrogen, in absolute ethanol (28.8 ml) at 45° C. A solution of 2-amidinopyridine hydrochloride (9.8 g; 63 mmol) in abs. ethanol (35 ml) is added and the mixture is heated at reflux for 1 hour. Portions, each of 8 ml, of the suspension are transferred to 8 flasks each containing a β-keto ester (7.88 mmol) in abs. ethanol (5 ml) (see Table 2 for amounts used). The suspensions are heated at reflux for 5 hours. After cooling to 25° C., the reaction mixture is evaporated to dryness and directly used in chlorination.







TABLE 2







β-Keto esters used















Amount


β-Keto ester
R1
R2
R
used





2-ethylacetoacetic acid ethyl ester
—CH3
—C2H5
—C2H5
1.27 g


acetoacetic acid ethyl ester
—CH3
H
—C2H5
1.04 g


trifluoroacetoacetic acid methyl ester
—CF3
H
—CH3
1.36 g


4-methyl-3-oxopentanoic acid methyl
-isopropyl
—CF3
—CH3
1.27 g


ester


4,4-dimethyl-3-oxopentanoic acid
-tert-butyl
H
—CH3
1.27 g


methyl ester


2-isopropylacetoacetic acid ethyl ester
—CH3
—
—C2H5
1.38 g




isopropyl


5-methoxy-3-oxopentanoic acid methyl
H3C—O—CH2—CH2—
H
—CH3
1.28 g


ester


benzoylacetic acid ethyl ester
phenyl
H
—C2H5
1.54 g









b: Synthesis of 4-chloro-2-(2-pyridyl)pyrimidines 



The crude products from a) are taken up in phosphorus oxychloride (5 ml, 54 mmol, in each case) and heated at 110° C. for 3 hours. After cooling to 25° C., the reaction mixtures are poured into 10 ml of ice-water and slowly adjusted to pH 8–9 using aqueous sodium hydroxide solution. The crude products obtained are extracted with dichloromethane (5×10 ml) and the organic extracts are washed with water (2×10 ml) and with saturated NaCl solution. After drying over MgSO4, the product is filtered off and evaporated to dryness. Because of the good purity of most of the products (see Table 3), further processing is carried out without further purification.







TABLE 3







HPLC purity of crude products (detection at 214 nm)












No.
R1
R2
HPLC purity [%]
















1
—CH3
—Et
>99



2
—CH3
—H
>99



3
—CF3
—H
>99



4
-isopropyl
—H
>99



5
-tert-butyl
—H
93



6
—CH3
—iPr
83



7
—CH2CH2—O—CH3
—H
98



8
-phenyl
—H
<5










c: Loading of Trityl Chloride-Polystyrene Resin (TCP) with Diamines 



In each case, 1 g of TCP resin (resin loading: 1.44 mmol/g) was shaken in abs. dichloromethane (5 ml) with a diamine (see Tab. 4; 5 equiv.; 7.2 mmol) for 24 hours at 25° C. The resin is washed with dichloromethane (5×), 1% HOAc/DCM, DMF and diethyl ether and dried in vacuo.







TABLE 4







Diamines used and weights thereof










diamine
amount used







n = 7
 938 mg



n = 8
1039 mg



n = 9
1140 mg



 n = 12
1443 mg










d: Reaction of the Diamine-TCP Resins with 4-chloro-2-(2-pyridyl)pyrimidines 



Diamine-TCP resins (50 mg; 72 μmol of diamine, in each case) are shaken in abs. dichloromethane (1 ml, in each case) with 4-chloro-2-(2-pyridyl)pyrimidines (3 equiv.; 216 μmol, in each case) and DIPEA (5 equiv.; 360 μmol) for 48 hours at 25° C. The resin is then filtered off, washed (DMF 5×, MeOH 5×, DCM 5×, diethyl ether 5×) and dried in vacuo. Cleaving is then carried out using 5% TFA/DCM (1.5 mL, in each case) for 1 hour at 25° C. The cleavage solutions are evaporated to dryness and the crude products are freeze-dried from tBuOH/water 4:1 with 10% HOAc and once from tBuOH/water 4:1.

e: Reaction of 4-chloro-2-(2-pyridyl)pyrimidines with monoamines 



4-Chloro-2-(2pyridyl)pyrimidines (72 μmol, in each case) are heated with monoamines (3 equiv.; 216 μmol, in each case) in abs. dioxane (0.5 ml) for 24 hours at 90° C. After cooling to 25° C., in order to remove the excess of amine, a scavenger resin (polystyrene aldehyde resin; resin loading 1.28 mmol/g; 3 equiv; 216 mmol; 170 mg) and also trimethyl orthoformate (2 equiv.; 144 μmol; 15 mg; 16 μl) and additional abs. THF (2 ml) are added. The reaction mixture is shaken for 24 hours at 25° C. After filtering, the filtrate is evaporated to dryness and the crude product is freeze-dried from tBuOH/water 4:1 with 10% HOAc and once from tBuOH/water 4:1.







TABLE 5







Amines and amounts used










Amine
Amount (216 μmol)
Amine
Amount (216 μmol)





H2N-(CH2)6-CH3
25 mg; 32 μL
H2N-(CH2)10-CH3
37 mg; 46 μL


H2N-(CH2)7-CH3
28 mg; 36 μL
H2N-(CH2)14-CH3
49 mg


H2N-(CH2)8-CH3
31 mg; 40 μL
benzylamine
23 mg; 24 μL


H2N-(CH2)9-CH3
34 mg; 43 μL
cyclohexylamine
21 mg; 25 μL


H2N-(CH2)11-CH3
40 mg; 50 μL
phenylethylamine
26 mg; 29 μL


H2N-(CH2)15-CH3
52 mg









All compounds prepared by the methods described above are listed in Tab. 1 and were characterised by means of HPLC and MS (Table 7, Purities). Some of the compounds were analysed using 1H-NMR spectroscopy (Table 6):









TABLE 6







Comp.

1H-NMR 250 MHz (CD3OD), δ [ppm]:











of f.
Structure
δ [ppm]
Multiplicity
Assignment





(35)




0.80–1.753.646.877.788.268.638.76
m, 19 Ht, 2 H ( J = 7 Hz)s, 1 Hm, 1 Hm, 1 Hm, 1 Hm, 1 H
—NH—CH—CH2—H arom.H arom.H arom.H arom.H arom.H arom.


 


(36)




0.80–1.753.636.877.738.218.628.77
m, 23 Ht, 2 H (J = 7 Hz)s, 1 Hm, 1 Hm, 1 Hm, 1 Hm, 1 H
—NH—CH—CH2—H arom.H arom.H arom.H arom.H arom.H arom.


 


(37)




0.80–1.733.636.857.688.158.598.73
m, 31 Ht, 2 H (J = 7 Hz)s, 1 Hm, 1 Hm, 1 Hm, 1 Hm, 1 H
—NH—CH—CH2—H arom.H arom.H arom.H arom.H arom.H arom.


 


(44)




0.80–1.803.726.617.738.138.588.87
m, 20 Ht, 2 H (J = 7 Hz)s, 1 Hm, 1 Hm, 1 Hm, 1 Hm, 1 H
—NH—CH—CH2—H arom.H arom.H arom.H arom.H arom.H arom.


 


(47)




0.70–1.703.566.447.577.968.408.69
m, 26 Ht, 2 H (J = 7 Hz)s, 1 Hm, 1 Hm, 1 Hm, 1 Hm, 1 H
—NH—CH—CH2—H arom.H arom.H arom.H arom.H arom.H arom.









Example 2
Determination of the Minimum Inhibitory Concentration (MIC Value) in Microtitre Plates
Nutrient Medium:
Casein-soybean flour-peptone broth for preparation of pre-cultures of test bacteria and yeast.
Mycological slant agar for the pre-culture of moulds
Examples of Test Organisms:
















Bacteria:
Staphylococcus hominis DMS 20328 (= SH)




Escherichia coli NCTC 8196 (= EC)










Procedure:

The test substances are pre-dissolved in dimethyl sulfoxide (DMSO) and tested in a dilution series of 1:2.
Bacteria and yeast are cultured overnight in CASO broth, the mould is cultured overnight on mycological slant agar, and washed off using 10 ml of 0.85% sodium chloride solution (+0.1% Triton X-100).
All the test organisms are adjusted to an organism count of 1–5×106 CFU/ml using 0.85% sodium chloride solution.
The test substances are pre-pipetted into microtitre plates in amounts of 8 μl per well.
Pre-diluted organism suspensions are diluted 1:100 in CASO broth (bacteria and yeast) or Sabouraud 2% glucose broth (mould) and are added in amounts of 192 μl per well to the test substances.
The test batches are incubated for 48 hours at 37° C. (bacteria and yeast) or for 5 days at 28° C. (mould).
After incubation, the growth is determined on the basis of the turbidity of the test batches (optical density) at 620 nm in a microplate reader.
The minimum inhibitory concentration (MIC value) is the concentration of substance at which there is found (compared to the growth of the control) an appreciable inhibition of growth (≦20% growth) of the test organisms.
One microtitre plate is used for each test organism and substance concentration. All the substances are tested in duplicate.
The results are compiled in Table 7:







TABLE 7







Minimum inhibitory concentration (MIC) of compounds tested [μg]














Comp.









of

S. hominis
E. coli


S. hominis
E. coli


formula
Purity [%]
[μg/mL]
[μg/mL]
No.
Purity [%]
[μg/mL]
[μg/mL]

















4
69
>120
>120
53
92
80
>80


5
63
>120
>120
54
99
30
120


6
63
n. d.
n. d.
55
66
7.5
60


7
60
120
120
56
89
3.75
>120


8
98
n. d.
n. d.
57
88
3.75
>120


9
74
7.5
>120
58
88
3.75
>120


10
79
5
>80
59
96
n. d.
n. d.


11
78
3.75
>120
60
94
3.75
120


12
98
7.5
120
61
71
>120
>120


13
95
120
>120
62
90
n. d.
n. d.


14
95
120
>120
63
90
3.75
>120


15
65
60
>120
64
80
30
>120


16
95
>120
>120
65
91
30
120


17
91
>80
>80
66
87
3.75
30


18
94
120
>120
67
82
5
20


19
93
15
60
68
83
7.5
>120


20
95
7.5
120
69
93
3.75
120


21
95
3.75
60
70
74
3.75
>120


22
95
3.75
120
71
71
5
>80


23
95
3.75
>120
72
77
15
>120


24
93
2.5
80
73
67
120
>120


25
90
15
>120
74
85
60
>120


26
95
60
>120
75
53
30
>120


27
96
60
>120
76
95
40
>80


28
98
>80
>80
77
92
30
120


29
>99
>80
>80
78
64
15
60


30
99
120
120
79
69
10
20


31
98
5
20
80
71
30
>120


32
99
3.75
>120
81
87
15
>120


33
99
2.5
>80
82
70
7.5
120


34
99
3.75
>120
83
65
7.5
>120


35
99
3.75
>120
84
56
15
120


36
98
60
>120
85
73
120
120


37
90
>120
>120
86
75
120
>120


38
99
60
>120
87
62
30
120


39
99
30
>120
88
90
120
120


40
75
120
>120
89
91
3.75
>120


41
94
120
>120
90
87
30
120


42
99
30
120
91
80
30
>120


43
91
7.5
60
92
84
3.75
>120


44
97
3.75
>120
93
83
7.5
>120


45
97
3.75
>120
94
83
>120
>120


46
97
3.75
>120
95
79
120
>120


47
97
5
>80
96
88
120
120


48
80
3.75
120
97
90
15
120


49
90
>120
>120
98
81
3.75
>120


50
94
15
>120
99
80
15
>120


51
95
30
>120


52
80
n. d.
n. d.





n. d. = not determined


Purity [%] = HPLC area percentages at a detection wavelength of 214 nm













TABLE 8







Minimum inhibitory concentrations (MIC in [μg/mL]) of selected compounds with


respect to further microorganisms









Compound of formula


















Microorganism
37
44
68
45
46
70
23
47
63
71
32





Staphylococcus aureus ATCC 9144
 15*
15
15
7.5
30
7.5
7.5
7.5
15
7.5
15


S. epidermidis ATCC 12228
7.5
15
15
7.5
30
7.5
7.5
3.75
30
7.5
7.5


Micrococcus luteus ATCC 9341
1.0
1.0
3.75
3.75
3.75
1.0
<0.5
<0.5
7.5
1.9
>0.5


Enterococcus hirae ATCC 10541
30
15
7.5
3.75
30
3.75
3.75
3.75
30
7.5
7.5


E. coli NCTC 8196
>30
>30
>30
>30
>60
>60
>60
>60
*60
>60
>60


Epidermophyton floccosum DSM 10709
>60
60
 60*
>60
60
*7.5
*15
*60
*15
60
*60


Trichophyton mentagrophytes ATCC 9533
>60
>60
>60
>60
>60
15
15
60
*60
*30
>60












Compound of formula


















Microorganism
56
9
33
57
10
34
58
11
35
43
83





Staphylococcus aureus ATCC 9144
3.75
15
15
1.9
15
>60
*1.9
7.5
*7.5
30
*15


S. epidermidis ATCC 12228
3.75
*15
3.75
1.9
15
*60
1.9
7.5
7.5
*15
15


Micrococcus luteus ATCC 9341
<0.5
3.75
<0.5
<0.5
<0.5
>0.5
<0.5
1.9
<0.5
3.75
3.75


Enterococcus hirae ATCC 10541
1.9
30
15
1.0
30
60
7.5
7.5
7.5
30
30


E. coli NCTC 8196
>60
>60
>60
>60
>60
>60
>60
>60
>60
>60
>60


Epidermophyton floccosum DSM 10709
*30
*15
>60
60
60
>60
>60
>60
>60
>60
>60


Trichophyton mentagrophytes ATCC 9533
*30
*30
>60
*60
60
>60
>60
>60
>60
>60
>60












Compound of formula

















Microorganism
12
60
21
69
77
22
30
54
78
7





Staphylococcus aureus ATCC 9144
15
15
120
7.5
>60
7.5
>60
*60
*60
>60


S. epidermidis ATCC 12228
*7.5
*7.5
120
7.5
>60
<3.75
>60
>60
*60
>60


Micrococcus luteus ATCC 9341
<3.75
<3.75
120
<3.75
>60
<3.75
60
15
>60
>60


Enterococcus hirae ATCC 10541
7.5
7.5
120
3.75
>60
<3.75
>60
>60
>60
>60


E. coli NCTC 8196
>60
>60
120
>60
>60
>60
>60
>60
>60
>60


Klebsiella pneumonia ATCC 4352
>60
>60
120
*60
>60
>60
>60
>60
>60
>60


Salmonella choleraesuis ATCC 10708
>60
>60
>120
>60
>60
>60
>60
>60
>60
>60


Pseudomonas aeruginosa CIP A-22
>60
>60
>120
>60
>60
>60
>60
>60
>60
>60


Candida albicans ATCC 10231
*60
>60
120
60
>60
15
>60
>60
>60
>60


Aspergillus niger ATCC 6275
>60
60
>60
*60
>60
60
>60
>60
>60
>30


Epidermophyton floccosum DSM 10709
*30
>60
>60
15
>60
*7.5
>60
>60
>60
>30


Trichophyton mentagrophytes ATCC 9533
60
>60
>60
*15
>60
15
>60
>60
>60
>30












Compound of formula















Microorganism
79
24
48
65
18
42
66
19





Staphylococcus aureus ATCC 9144
*60
<3.75
<3.75
>60
>60
60
60
60


S. epidermidis ATCC 12228
30
3.75
<3.75
>60
>60
60
60
60


Micrococcus luteus ATCC 9341
60
<3.75
<3.75
>60
>60
*15
*30
7.5


Enterococcus hirae ATCC 10541
>60
*15
<3.75
>60
>60
>60
>60
60


E. coli NCTC 8196
60
>60
>60
>60
>60
>60
>60
>60


Klebsiella pneumonia ATCC 4352
>60
>60
>60
>60
>60
>60
>60
>60


Salmonella choleraesuis ATCC 10708
>60
>60
>60
>60
>60
>60
>60
>60


Pseudomonas aeruginosa CIP A-22
>60
>60
>60
>60
>60
>60
>60
>60












Compound of formula















Microorganism
79
24
48
65
18
42
66
19





Candida albicans ATCC 10231
*30
30
*15
>60
>60
>60
>60
7.5


Aspergillus niger ATCC 6275
>60
>60
>60
>60
>60
>60
>60
>60


Epidermophyton floccosum DSM 10709
>60
60
*60
>60
>60
>60
>60
>60


Trichophyton mentagrophytes ATCC 9533
>60
>60
*60
>60
>60
>60
>60
>60









Compound of formula













Microorganism
92
93
89
90
98
99





Staphylococcus aureus ATCC 9144
3.75
15
7.5
*30
1.9
7.5


S. epidermidis ATCC 12228
*1.9
7.5
7.5
*30
1.9
3.75


Micrococcus luteus ATCC 9341
<0.5
1.9
1.9
15
<0.5
1.0


Enterococcus hirae ATCC 10541
3.75
15
7.5
30
1.9
3.75


E. coli NCTC 8196
>120
>120
>60
>60
120
>60


Klebsiella pneumonia ATCC 4352
120
>120
60
>60
120
>60


Salmonella choleraesuis ATCC 10708
>120
>120
>60
>60
>120
>60


Pseudomonas aeruginosa CIP A-22
>120
>120
>60
>60
>120
>60


Candida albicans ATCC 10231
15
*120
15
*60
30
>60


Aspergillus niger ATCC 6275
*60
>60
30
>120
>60
>60


Epidermophyton floccosum DSM 10709
15
>60
15
60
15
*60


Trichophyton mentagrophytes ATCC 9533
15
>60
*7.5
>120
>60
>60





*significant inhibition of growth, but not complete inhibition






Example 3
Determination of the Bactericidal Activity of Selected Compounds
Test Method:
Nutrient Medium:
Casein-soybean flour-peptone broth for preparation of pre-cultures of test bacteria
Examples of Test Organisms:


    Staphylococcus aureus ATCC 6538
    Escherichia coli ATCC 10536
    Salmonella choleraesuis ATCC 10708

Procedure:



The test substances are dissolved in dimethyl sulfoxide (DMSO) and tested in a concentration of 120 μg/ml.
Bacteria are incubated overnight in CASO broth and adjusted to an organism count of 1–5×105 CFU/ml using 0.85% sodium chloride solution.
The test substances are pre-pipetted into microtitre plates in amounts of 8 μl per well.
The adjusted test organism suspensions are added in amounts of 192 μl per well to the test substances and mixed. After defined contact times, the test batches are mixed, an aliquot is withdrawn and diluted in several steps in a dilution series of 1:10 in a suitable inactivation medium.
The test plates are incubated for 24 hours at 37° C.
After incubation, the growth is determined on the basis of the turbidity of the test batches (optical density) at 620 nm in a microplate reader.
On the basis of the number of growth-exhibiting steps in the dilution series, the reduction in the test organism concentration is determined in powers of ten (log value).
One microtitre plate is used for each test organism.
All the substances are tested in duplicate.







TABLE 9







Logarithmic reduction in organism count after contact for 30


minutes at a substance concentration of 120 μg/mL









Microorganism











S. choleraesuis
E. coli
S. aureus


Compound of formula
ATCC 10708
NCTC 8196
ATCC 6538





(12)
<1
<1
1–2


(37)
<1
<1
1–2


(44)
<1
<1
1–2


(60)
<1
<1
<1


(68)
<1
<1
≦1


(21)
<1
<1
1–2


(45)
<1
<1
1–2


(69)
≦1
<1
1–2


(77)
<1
<1
>3


(22)
<1
<1
1–2


(30)
≦1
<1
≦1


(46)
<1
<1
≦1


(54)
≦1
≦1
2–3


(70)
<1
≦1
≦1


(78)
<1
≦1
>3


 (7)
<1
≦1
2


(23)
<1
<1
3


(47)
<1
<1
1


(63)
<1
≦1
<1


(71)
<1
<1
2


(24)
<1
≦1
2


(32)
≦1
<1
<1


(48)
<1
<1
1


(57)
<1
<1
1


 (9)
<1
<1
<1


(33)
<1
<1
<1


(57)
<1
<1
<1


(65)
<1
<1
3


(10)
<1
<1
1–2


(18)
<1
<1
1


(34)
<1
<1
<1


(42)
<1
≦1
2


(58)
≦1
≦1
1


(11)
<1
≦1
1–2


(19)
<1
≦1
2–3


(35)
<1
<1
<1


(43)
<1
<1
3


(83)
<1
≦1
2


(92)
≦1
<1
>3


(93)
<1
≦1
2


(89)
≦1
≦1
2


(90)
<1
<1
2


(98)
2–3
1–2
1


(99)
<1
≦1
2

## Claims

1. A method for the antimicrobial treatment, deodorisation and disinfection of the skin, mucosa and hair, which comprises applying an antimicrobially effective amount of a compound of the formula (1) thereto 



wherein
R1 and R2 are each independently of the other hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C20alkyl, C1–C20alkoxy, C2–C20alkenyl, C2–C20alkynyl, C3–C18cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; mono- or di-C1–C20alkylamino; C1–C6alkylamino-C1–C20alkyl; halogen; phenyl; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl-C1–C20alkyl, phenoxy or phenyl-C1–C20alkoxy; or R1 and R2 form a polymethylene chain of formula —(CH2)m— wherein m=2–12;
R3 is unsubstituted C7–C20alkyl; or amino-substituted C2–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted C1–C20alkyl, C2–C20alkenyl, C2–C20alkynyl, C3–C20cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl, C1–C20alkoxy-C1–C6alkyl or R7R8N—C1–C20alkyl, phenyl, phenyl-C1–C20alkyl or phenoxy-C1–C20alkyl;
R5 and R6 are hydrogen; and
R7 and R8 are each independently of the other C1–C20alkyl; C3–C20alkenyl; C3–C20alkynyl; C3–C7cycloalkyl; C3–C20cycloalkyl-C1–C4alkyl; phenyl; or phenyl-C1–C4alkyl.

2. A method according to claim 1, wherein the compound of formula (1) is used for disinfection and deodorisation.

3. A method for the preservation of personel care preparations, which comprises adding a compound of formula (1) to said preparation 



wherein
R1 and R2 are each independently of the other hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C20alkyl, C1–C20alkoxy, C2–C20alkenyl, C2–C20alkynyl, C3–C18cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; mono- or di-C1–C20alkylamino; C1–C6alkylamino-C1–C20alkyl; halogen; phenyl; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl-C1–C20alkyl, phenoxy or phenyl-C1–C20alkoxy; or R1 and R2 form a polymethylene chain of formula —(CH2)m— wherein m=2–12;
R3 is unsubstituted C7–C20alkyl; or amino-substituted C2–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted C1–C20alkyl, C2–C20alkenyl, C2–C20alkynyl, C3–C20cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl, C1–C20alkoxy-C1–C6alkyl or R7R8N—C1–C20alkyl, phenyl, phenyl-C1–C20alkyl or phenoxy-C1–C20alkyl;
R5 and R6 are hydrogen; and
R7 and R8 are each independently of the other C1–C20alkyl; C3–C20alkenyl; C3–C20alkynyl; C3–C7cycloalkyl; C3–C20cycloalkyl-C1–C4alkyl; phenyl; or phenyl-C1–C4alkyl.

4. A method according to claim 3 which comprises adding an antimicrobially effective amount of formula (1) to washing and cleaning formulations.

5. A personal care preparation comprising from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1) 



wherein
R1 and R2 are each independently of the other hydrogen; unsubstituted or mono- or poly-halo-substituted C1–C20alkyl, C1–C20alkoxy, C2–C20alkenyl, C2–C20alkynyl, C3–C18cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl; hydroxy; C1–C6alkoxy-C1–C20alkyl; carboxy; C1–C6alkyloxycarbonyl; cyano; mono- or di-C1–C20alkylamino; C1–C6alkylamino-C1–C20alkyl; halogen; phenyl; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted phenyl-C1–C20alkyl, phenoxy or phenyl-C1–C20alkoxy; or R1 and R2 form a polymethylene chain of formula —(CH2)m— wherein m=2–12;
R3 is unsubstituted C7–C20alkyl; or amino-substituted C2–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; unsubstituted or C1–C5alkyl-, halo- or hydroxy-substituted C1–C20alkyl, C2–C20alkenyl, C2–C20alkynyl, C3–C20cycloalkyl, C3–C7cycloalkyl-C1–C20alkyl, C1–C20alkoxy-C1–C6alkyl or R7R8N—C1–C20alkyl, phenyl, phenyl-C1–C20alkyl or phenoxy-C1–C20alkyl;
R5 and R6 are hydrogen; and
R7 and R8 are each independently of the other C1–C20alkyl; C3–C20alkenyl; C3–C20alkynyl; C3–C7cycloalkyl; C3–C20cycloalkyl-C1–C4alkyl; phenyl; or phenyl-C1–C4alkyl;

and cosmetically tolerable adjuvants.

6. An oral composition comprising from 0.01 to 15% by weight, based on the total weight of the composition, of a compound of formula (1) according to claim 5, and orally tolerable adjuvants.

7. A method according to claim 1, wherein
R1 and R2 are each independently of the other hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3;
R3 is unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; or C1–C20alkyl;
R5 and R6 are hydrogen;
R7 and R8 are each independently of the other C1–C20alkyl; and m is from 1 to 4.

8. A method according to claim 3, wherein
R1 and R2 are each independently of the other hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3;
R3 is unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; or C1–C20alkyl;
R5 and R6 are hydrogen;
R7 and R8 are each independently of the other C1–C20alkyl; and m is from 1 to 4.

9. A composition according to claim 5, wherein
R1 and R2 are each independently of the other hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3;
R3 is unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; or C1–C20alkyl;
R5 and R6 are hydrogen;
R7 and R8 are each independently of the other C1–C20alkyl; and m is from 1 to 4.

10. A composition according to claim 6, wherein
R1 and R2 are each independently of the other hydrogen, methyl, ethyl, isopropyl, tert-butyl, CF3 or the radical —(CH2)m—O—CH3;
R3 is unsubstituted or amino-substituted C7–C20alkyl or R7R8N—C7–C20alkyl;
R4 is hydrogen; or C1–C20alkyl;
R5 and R6 are hydrogen;
R7 and R8 are each independently of the other C1–C20alkyl; and m is from 1 to 4.